# ACADIA Pharmaceuticals Named to Forbes Magazine's List of World's Most Innovative Growth Companies

July 25, 2017

SAN DIEGO--(BUSINESS WIRE)--Jul. 25, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it has been ranked 11th on *Forbes* Magazine's 2017 list of the World's Most Innovative Growth Companies. ACADIA is a biopharmaceutical company dedicated to developing and delivering innovative medicines to address unmet medical needs in central nervous system (CNS) disorders.

"We are pleased to be recognized by *Forbes* as a leader in innovation," said Steve Davis, ACADIA's President and Chief Executive Officer. "Being named to this list is a testament to our team's hard work and commitment to developing transformational medicines that improve the lives of patients suffering from major CNS disorders. Our breakthrough antipsychotic NUPLAZID is the first drug approved by the FDA for patients suffering from Parkinson's disease psychosis. We are currently studying the drug in five additional disease states including unmet needs in Alzheimer's disease, schizophrenia and depression."

*Forbes'* ranking is based on the "innovation premium" of each company, and only includes industries that are known to invest in innovation. To qualify for consideration in the annual list, companies must have at least seven years of public financial data and a market capitalization between $2 billion and $10 billion.

*About ACADIA Pharmaceuticals*

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.com to which we regularly post copies of our press releases as well as additional information and through which interested parties can subscribe to receive e-mail alerts.

*Forward-Looking Statements*

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the benefits to be derived from ACADIA's commercial products and development compounds, including NUPLAZID. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development, and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA's annual report on Form 10-K for the year ended December 31, 2016 as well as ACADIA's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

**Important Safety Information and Indication for NUPLAZID (pimavanserin) tablets**

**WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS**

**Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson's disease psychosis.**

NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Contraindication: NUPLAZID is contraindicated in patients with a history of hypersensitivity reaction to pimavanserin or any of its components. Reactions have included rash, urticaria, tongue swelling, circumoral edema, and throat tightness.

QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

Adverse Reactions: The most common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

Drug Interactions: Strong CYP3A4 inhibitors (eg, ketoconazole) increase NUPLAZID concentrations. Reduce the NUPLAZID dose by one-half. Strong CYP3A4 inducers may reduce NUPLAZID exposure, monitor for reduced efficacy. Increase in NUPLAZID dosage may be needed.

Renal Impairment: No dosage adjustment for NUPLAZID is needed in patients with mild to moderate renal impairment. Use of NUPLAZID is not recommended in patients with severe renal impairment.

Hepatic Impairment: Use of NUPLAZID is not recommended in patients with hepatic impairment. NUPLAZID has not been evaluated in this patient population.

Pregnancy: Use of NUPLAZID in pregnant women has not been evaluated and should therefore be used in pregnancy only if the potential benefit justifies the potential risk to the mother and fetus.

Pediatric Use: Safety and efficacy have not been established in pediatric patients.

Dosage and Administration: Recommended dose: 34 mg per day, taken orally as two 17-mg tablets once daily, without titration.

For additional Important Safety Information, including boxed warning, please see the full Prescribing Information for NUPLAZID at https://www.nuplazid.com/pdf/NUPLAZID_Prescribing_Information.pdf.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170725005364/en/

Source: ACADIA Pharmaceuticals Inc.

Investor Contact:
*ACADIA Pharmaceuticals Inc.*
*Lisa Barthelemy*
*(858) 558-2871*
*ir@acadia-pharm.com*
or
Media Contact:
*Taft Communications*
*Bob Laverty*
*(609) 558-5570*
*bob@taftcommunications.com*